Article Figures & Data
Figures
- Figure 1.
Study Design
Data presented in No. (%).
DB, double-blind.
Adapted by permission from Macmillan Publishers Ltd: Nerophsychopharmacology. Koblan KS et al. Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults. Advance online publication 3 June 2015; doi: 10.1038/npp.2015.124. Copyright (2015).
- Figure 2.
Primary Outcome
The primary efficacy measure of ADHD RS-IV (with adult prompts) total score was reduced by dasotraline 4 mg (adjusted P = .076) and 8 mg (adjusted P = .019) at 4 wk compared with placebo.
ADHD RS-IV, Attention Deficit Hyperactivity Disorder Rating Scale version IV; LS, least squares.
aBaseline mean, 36.8.
bBaseline mean, 36.6.
cBaseline mean, 36.7.
*P < .05.
Adapted by permission from Macmillan Publishers Ltd: Nerophsychopharmacology. Koblan KS et al. Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults. Advance online publication 3 June 2015; doi: 10.1038/npp.2015.124. Copyright (2015).
Tools
Table of contents
Cited By...
- No citing articles found.